Drug intelligence / Profile preview

SMTP-44D

Development stage
Preclinical
Lead developer
TMS
Modality
Small Molecules
Administration
Oral
01

Overview

SMTP-44D is a small molecule derived from the fungus Stachybotrys microspora, belonging to the triprenyl phenol family. It acts as a **soluble epoxide hydrolase (sEH) inhibitor** and displays robust **antioxidant and anti-inflammatory properties**. Its mechanisms involve the inhibition of sEH, which increases beneficial epoxyeicosatrienoic acids (EETs) and decreases pro-inflammatory dihydroxyeicosatrienoic acids (DHETs), reducing oxidative stress, inflammation, and apoptosis. SMTP-44D also interferes with the receptor for advanced glycation end products (**RAGE**) pathway by blocking the interaction of advanced glycation end products (**AGEs**) with RAGE, contributing to neuroprotection in diabetic neuropathy and reduction of atherosclerotic plaque formation via suppression of **Cdk5-CD36**-mediated oxidized LDL uptake in macrophages. It is currently being investigated preclinically for conditions such as diabetic neuropathy and atherosclerosis[1][2][3][4].

Other names
Stachybotrys microspora triprenyl phenol-44D
02

Targets

CD36 (CD36 antigen)CDK5 (Cyclin-dependent kinase 5)AGER (RAGE)EPHX2 (Soluble epoxide hydrolase)

Beyond the preview

Go deeper on SMTP-44D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMTP-44D.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call